Optogenetic Therapy Shows Early Promise for Retinitis Pigmentosa-Associated Blindness
Oct 7, 2026
A small clinical study found that an optogenetic treatment paired with specialized goggles safely improved light sensitivity in some people with advanced retinitis pigmentosa, regardless…
Read More –Age-Based Genetic Testing Misses 72% of Patients with Inherited Cancer Variants
Oct 8, 2026Glioblastoma Drug Uses Unexpected Mechanism
Oct 7, 2026Chemotherapy Can Boost Cancer Vaccines via T Cells
Oct 7, 2026tRNA Influences If Prostate Cancer Becomes Resistant to Treatment
Oct 7, 2026Enzyme Biomarker May Predict CDK4/6 Inhibitor Resistance in Breast Cancer
Oct 7, 2026Matt Begemann: The Cancer-Killing CRISPR
Oct 7, 2026HPV Vaccination Prevents Major Pregnancy Complications
Oct 7, 2026
Mitochondria Closely Linked with Cancer Progression
Oct 7, 2026
Statin Use Linked to Lower Glaucoma Risk and Less Need for Intensive Treatment
Oct 6, 2026
Experimental Peptide Quiets Chronic Pain Signals While Preserving Protective Pain
Oct 6, 2026
Ultra-Processed Foods Alter Metabolic and Brain Responses Despite Matched Nutrients
Oct 5, 2026
Reversing a Cellular Aging Process Could Help Treat Fibrotic Disease
Oct 5, 2026
Highly Multiplexed Droplet Digital PCR for Ultra-Sensitive NSCLC Biomarker Detection in Research Workflows
In this IPM webinar, two experts will discuss the growing role of ddPCR in clinical research and translational oncology.
Surbhi Jain, PhD, MBBS
Staff Scientist
Bio-Rad Laboratories
Prithwish Pal, PhD
Director, Global Product Marketing – Oncology
Bio-Rad Laboratories
Riaan’s Therapeutic Odyssey – Chapter 5: The Family
Oct 1, 2026In the final installment of this series, Riaan and his family face the unknown after five years of developing a genetic medicine for Cockayne syndrome.
Asthma Biologic Interacts with Common Genetic Variant in Children
Oct 1, 2026The frequently used biologic drug mepolizumab may cause an exaggerated inflammatory response in children with severe asthma who carry an incredibly common genetic variant when…
Hyperreactive Astrocytes Identified as Potential Driver of Tuberous Sclerosis Brain Lesions
Sep 30, 2026Brain organoids and patient tissue revealed that TSC2 loss produces hyperreactive astrocytes that may drive inflammation and cortical lesion formation in tuberous sclerosis complex.
Podcast Series
Behind the Breakthroughs
Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine, as he uncovers the stories behind the pioneers driving the precision medicine revolution.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter.
Whole Genome Sequencing Diagnoses 47% Neurological Pediatric Cases
CRISPR-Based Test Offers Fast Antimicrobial Resistance Detection in Low-Resource Settings
Urine RNA Test Could Detect Bladder Cancer and Predict Treatment Response


